@article{0273ee9f5bd84194a3e63c04be081124,
title = "KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors",
abstract = "Living kidney donation is widely practiced throughout the world. During the past 2 decades, various groups have provided guidance about the evaluation and care of living donors. However, during this time, our knowledge in the field has advanced substantially and many agreed on the need for a comprehensive, unifying document. KDIGO (Kidney Disease: Improving Global Outcomes) addressed this issue at an international level with the publication of its clinical practice guideline on the evaluation and care of living kidney donors. The KDIGO work group extensively reviewed the available literature and wrote a series of guideline recommendations using various degrees of evidence when available. As has become recent practice, NKF-KDOQI (National Kidney Foundation–Kidney Disease Outcomes Quality Initiative) convened a work group to provide a commentary on the KDIGO guideline, with a focus on how these recommendations apply in the context of the United States. In the United States, the United Network for Organ Sharing (UNOS) guides and regulates the practice of living kidney donation. While the KDIGO guideline for the care of living kidney donors and UNOS policy are similar in most aspects of the care of living kidney donors, several important areas are not consistent or do not align with common practice by US transplantation programs in areas in which UNOS has not set specific policy. For the time being, and recognizing the value of the KDIGO guidelines, US transplantation programs should continue to follow UNOS policy.",
keywords = "Living kidney donation, albuminuria, best practices, clinical practice guideline, contraindication, diabetes, donor candidate, donor counseling, donor evaluation, donor follow-up, donor safety, donor selection, end-stage renal disease (ESRD), ethics, genetic risk, glomerular filtration rate (GFR), hypertension, informed consent, kidney donor, kidney failure, kidney function, long-term risk, nephrectomy, postdonation monitoring, pregnancy, psychosocial evaluation, Humans, Renal Insufficiency, Chronic/surgery, Living Donors, Kidney Transplantation/standards, Tissue and Organ Procurement/standards, Practice Guidelines as Topic",
author = "Mandelbrot, {Didier A.} and Reese, {Peter P.} and Neetika Garg and Thomas, {Christie P.} and Rodrigue, {James R.} and Carrie Schinstock and Mona Doshi and Matthew Cooper and John Friedewald and Naik, {Abhijit S.} and Kaul, {Daniel R.} and Ison, {Michael G.} and Rocco, {Michael V.} and Jennifer Verbesey and Hladunewich, {Michelle A.} and Ibrahim, {Hassan N.} and Poggio, {Emilio D.}",
note = "Funding Information: No dedicated financial support was required for the development of this commentary. Dr Rodrigue is supported by award no. R01DK114877 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Funding Information: Didier A. Mandelbrot, MD, Peter P. Reese, MD, MSCE, Neetika Garg, MD, Christie P. Thomas, MD, James R. Rodrigue, PhD, Carrie Schinstock, MD, Mona Doshi, MD, Matthew Cooper, MD, John Friedewald, MD, Abhijit S. Naik, MD, MPH, Daniel R. Kaul, MD, Michael G. Ison, MD, Michael V. Rocco, MD, MSCE, Jennifer Verbesey, MD, Michelle A. Hladunewich, MD, Hassan N. Ibrahim, MD, and Emilio D. Poggio, MD. No dedicated financial support was required for the development of this commentary. Dr Rodrigue is supported by award no. R01DK114877 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Dr Reese discloses investigator-initiated grants from Merck and AbbVie (to the University of Pennsylvania to support research on transplantation of HCV-infected organs) and from CVS Caremark and Merck (to the University of Pennsylvania to support research on medication adherence, with a focus on statins). Dr Thomas discloses a research grant from Shire Viropharma. Dr Friedewald discloses research grants from Shire, Abbvie, and Vaiteris; speaker fees from Novartis and Sanofi; and consultancy and ownership in Transplant Genomics, Inc. Dr Kaul discloses research grants from Merck, Shire, and Chimerix. Dr Ison discloses research grants from AiCuris, Chimerix, Emergent BioScience, Genentech/Roche, Gilead, Janssen and Shire; receipt of royalties from UpToDate for chapters on PIV; and consultancy for Celltrion, Genentech/Roche, Janssen, Shionogi, Viracor Eurofins, and VirBio. Dr Rocco discloses consultancy for Fibrogen, Abbvie, and Baxter, and clinical trials with Bayer and Boehringer Ingelheim. Dr Poggio discloses speakers? fees from Gador Argentina and CareDx, and consultancy for Reata-Fallon Medical LLC and Renalytix AI Inc. The remaining authors declare that they have no relevant financial interests. Dr Rocco is KDOQI Chair and a member of the NKF Scientific Advisory Board. Guideline recommendations included in this article originally were published in Transplantation, are ? 2017 KDIGO, and were reproduced with permission from KDIGO. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIDDK or the National Institutes of Health. The NIDDK had no involvement in the writing of this manuscript or the decision to submit the manuscript for publication. Received October 1, 2019, following review and approval of the NKF Scientific Advisory Board (membership listed at kidney.org/about/sab; as an author and an AJKD editor, respectively, Drs Rocco and Feldman were recused). Accepted October 2, 2019, after editorial review by a Deputy Editor. Publisher Copyright: {\textcopyright} 2019 National Kidney Foundation, Inc.",
year = "2020",
month = mar,
doi = "10.1053/j.ajkd.2019.10.005",
language = "English (US)",
volume = "75",
pages = "299--316",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders",
number = "3",
}